Figure 3.
Best overall response by baseline tumor mutation status. Distribution of patients by CR, PR, stable disease, or PD according to wild-type or mutational status of EZH2, TP53, BCL2, CREBBP, KMT2D, and TNFRSF14. CCOD: 2 May 2023. Mut, mutated; SD, stable disease; WT, wild-type.

Best overall response by baseline tumor mutation status. Distribution of patients by CR, PR, stable disease, or PD according to wild-type or mutational status of EZH2, TP53, BCL2, CREBBP, KMT2D, and TNFRSF14. CCOD: 2 May 2023. Mut, mutated; SD, stable disease; WT, wild-type.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal